Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Evaluation of antiaggregatory activity of flavonoid aglycone series

  • Mirza Bojić1,
  • Željko Debeljak1, 2,
  • Maja Tomičić3,
  • Marica Medić-Šarić1Email author and
  • Siniša Tomić4
Nutrition Journal201110:73

DOI: 10.1186/1475-2891-10-73

Received: 15 March 2011

Accepted: 11 July 2011

Published: 11 July 2011

Abstract

Background

Among natural compounds, present in every day diet, flavonoids have shown beneficial effect in prevention of cardiovascular diseases that can be attributed, at least partially to the described antiaggregatory activity i.e. antiplatelet effects of flavonoids. Due to the ever increasing pharmacological interest in antiplatelet agents a systematic experimental evaluation of large flavonoid series is needed.

Methods

A set of thirty flavonoid aglycones has been selected for the evaluation. All measurements of aggregation were done under standardized and firmly controlled in vitro conditions. The whole blood samples, multiple platelet functional analyzer and adenosine diphosphate (ADP) as a weak agonist of aggregation were selected for this purpose.

Results

The results were expressed as minimal concentration of flavonoid that can significantly lower the platelet aggregation compared to the corresponding untreated sample (minimal antiaggregatory concentration - MINaAC). All analyzed flavonoids exhibited antiaggregatory activity MINaAC ranging from 0.119 μM to 122 μM, while the most potent representatives were 3,6-dihydroxyflavone (0.119 μM) and syringetin (0.119 μM).

Conclusions

Measurable antiplatelet activity established at submicromolar flavonoid concentrations suggests that even a dietary consumption of some flavonoids can make an impact on in vivo aggregation of platelets. These findings also point out a therapeutical potential of some flavonoids.

Background

In the developed countries most of the older population is affected by cardiovascular diseases. Platelets are involved in haemostasis, thrombosis and inflammatory processes, hence as a consequence of that physiological role heart stroke and cerebrovascular insult can occur. Most commonly used drug in prevention of mentioned diseases is acetylsalicylic acid while clopidogrel represents another therapeutic option. Neither of these drugs is free of side effects, thus the search for new and safer drug from this group continues [1]. From the natural compounds, present in every day diet, polyphenols, mainly flavonoids (Figure 1), have shown beneficial effect in prevention of cardiovascular diseases [27]. Flavonoids naturally occur in a free form (aglycones) or bound to a sugar moiety via hydroxyl groups (glycosides).
https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_Fig1_HTML.jpg
Figure 1

Basic structure of flavonoids. Flavonoids are divided into classes based on the structure of ring C. Basic structure corresponds to flavan which are named flavanols (catechins) if hydroxylated at position C3. Flavanones have keto group on position C4. If the double bond C2 = C3 is present in structure flavanols and flavanones are named flavones and flavanonols, respectively. Isoflavonoids have B-ring at the position C3.

Flavonoid antiplatelet activity can be attributed to the increased production of prostacyclin by endothelian cells. Prostacyclin decreases aggregation via synthesis of cAMP - increased concentration of cAMP inhibits the expression of platelet GPIIb/IIIa receptors [6]. In vitro inhibition of cyclooxygenase, lipooxygenase, thyrosine kinase, phosphodiesterase or phospholipase by flavonoids has also been documented and connected to their antiplatelet activity [812]. Although different possible mechanisms have been analyzed a unique mechanism of antiaggregatory activity of flavonoids has not been undoubtedly proven yet.

There are also doubts about antiaggregatory effectiveness in vivo, due to high concentrations of flavonoids that have been used in experiments in vitro (10 - 1000 μM) that can not be reached in vivo after oral intake (0.6 μM) [13].

Most of the research on antiaggregatory effect of flavonoids has been done using Born spectrophotometric aggregometry. A major disadvantage of this method is usage of platelets rich plasma (PRP) instead of whole blood. Furthermore, most authors tested a range or even a single concentration of flavonoids, and often the series of tested flavonoids were small, thus limiting the overall interpretation of the results [9, 1418]. Finally, influence of biological variability has not been evaluated.

In this paper our objective was to analyse antiaggregatory effect of a relatively large set consisting of 30 flavonoid aglycons. Instead of Born method impedance aggregometry has been chosen as it enables usage of whole blood. This method reduces problems related to lack of standardization of PRP preparation and provides insight to possible interactions of flavonoids with blood components other than platelets. Biological triplicates of all experiments have been made on blood samples taken from three different blood donors. Along with the statistical evaluation of difference between treated and untreated samples this approach clearly minimizes chance effects caused by large biological variability.

Methods

Materials

A set of thirty flavonoids has been tested. Structures and the names of the suppliers are stated in the Table 1, Table 2, Table 3, Table 4 and Table 5. Clopidogrel, an ADP-receptor antagonist, was used as a positive control. This substance was a kind gift of HALMED, Croatia. All standards solutions were prepared by dissolving and semi-dissolution (1/2n) in dimethyl sulfoxide (DMSO, Sigma-Aldrich, Switzerland) in the concentration range of 500 mM to 30 nM depending of the flavonoid analyzed. Final concentration of DMSO in all experiments was 3%.
Table 1

Antiaggregatory activity of flavanons

Flavanons

Structure

MINaAC /μM

p

Hesperetina

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq1_HTML.gif

1.907

0.035

Homoeriodictyolb

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq2_HTML.gif

7.629

0.003

Isosakuranetinb

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq3_HTML.gif

0.954

0.037

Pinocembrinc

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq4_HTML.gif

15.259

0.010

Pinocembrin-7-methyletherc

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq5_HTML.gif

0.954

0.025

Minimal antiaggregatory concentration of flavanons expressed in μM with statistical significance (p).

Flavonoids purchased from aSigma-Aldrich, Switzerland, bBioChemika, Switzerland, cExtrasynthese, France.

Table 2

Antiaggregatory activity of flavones

Flavones

Structure

MINaAC /μM

p

6-hydroxyflavonea

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq6_HTML.gif

0.954

0.030

7-hydroxyflavonea

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq7_HTML.gif

15.259

0.038

Acacetinb

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq8_HTML.gif

3.815

0.013

Apigeninc

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq9_HTML.gif

3.815

0.037

Chrysinc

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq10_HTML.gif

3.815

0.016

Chrysin dimethyletherd

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq11_HTML.gif

1.907

0.025

Diosmetind

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq12_HTML.gif

7.629

0.021

Flavonec

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq13_HTML.gif

3.815

0.037

Luteolind

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq14_HTML.gif

7.629

0.029

Tangeretinb

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq15_HTML.gif

30.518

0.029

Tectochrysind

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq16_HTML.gif

0.954

0.013

Minimal antiaggregatory concentration of flavones expressed in μM with statistical significance (p).

Flavonoids purchased from aChromaDex, USA, bBioChemika, Switzerland, cFluka, Germany, dExtrasynthese, France.

Table 3

Antiaggregatory activity of flavanonols

Flavanonols

Structure

MINaAC /μM

p

3-hydroxyflavonea

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq17_HTML.gif

1.907

0.019

3,6-dihydroxyflavonea

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq18_HTML.gif

0.119

0.005

3,7-dihydroxyflavonea

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq19_HTML.gif

1.907

0.001

Fisetinb

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq20_HTML.gif

122.070

0.003

Galanginc

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq21_HTML.gif

122.070

0.008

Isorhamnetind

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq22_HTML.gif

7.629

0.029

Quercetine,*

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq23_HTML.gif

15.259

0.047

Rhamnetind

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq24_HTML.gif

0.954

0.041

Syringetind

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq25_HTML.gif

0.119

0.013

Minimal antiaggregatory concentration of flavanonols expressed in μM with statistical significance (p).

Flavonoids purchased from aChromaDex, USA, bExtrasynthese, France, cSigma-Aldrich, Switzerland, dBioChemika, Switzerland, eFluka, Germany; *in the form of quercetin dihydrate.

Table 4

Antiaggregatory activity of isoflavones

Isoflavones

Structure

MINaAC /μM

p

Daidzeina

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq26_HTML.gif

15.259

0.048

Formononetina

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq27_HTML.gif

7.629

0.043

Genisteina

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq28_HTML.gif

30.518

0.013

Prunetina

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq29_HTML.gif

7.629

0.033

Minimal antiaggregatory concentration of isoflavones expressed in μM with statistical significance (p).

Flavonoids purchased from aExtrasynthese, France.

Table 5

Antiaggregatory activity of positive control and catechin

Substance

Structure

MINaAC /μM

p

Epicatechina

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq30_HTML.gif

1.907

0.030

Clopidogrel

https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_IEq31_HTML.gif

0.019

0.029

Minimal antiaggregatory concentration of positive control and catechin expressed in μM with statistical significance (p).

Flavonoid purchased from aSigma-Aldrich, Switzerland.

ADP was obtained from Dynabyte, Germany, and saline-CaCl2 (0.003 M CaCl2 in 0.9% NaCl) from Croatian Institute of Transfusion Medicine, Croatia.

Freshly taken citrated blood (final citrate concentration 0.129 mol/L) was used for the measurement of aggregation each time from three different healthy volunteers per each flavonoid sample. This work was approved by Ethical comities of Croatian Institute of Transfusion Medicine and Faculty of Pharmacy and Biochemistry, University of Zagreb. A total number of 100 volunteers participated in this research. All volunteers gave informed written consent.

Experimental procedure

Platelet aggregation was analyzed by Multiplate® analyzer (Dynabyte, Germany). Generic procedure was used: 300 μL of blood was incubated for 6 minutes with 20 μL flavonoid solution and 300 μL of saline-CaCl2 preheated at 37°C. For negative control (untreated sample) 20 μL of solvent - DMSO was used (final concentration 3%). Aggregation cascade was induced by adding 20 μL of adenosine diphosphate reagent (ADPtest; final concentration of ADP 6.5 μM). Aggregation was measured for 6 minutes and expressed as area under curve in arbitrary units (AU).

Data analysis

The results of antiaggregatory effect of flavonoids were expressed as minimal antiaggregatory concentration (MINaAC) that presents the lowest concentration of flavonoid which can cause statistically significant reduction of aggregation when compared to the untreated sample. Procedure for determination of MINaAC is illustrated on Figure 2. Statistical analysis was performed using paired Student's t-test within R v2.8.1 environment (Austria). Normal distribution of aggregation on ten healthy volunteers was checked using Shapiro-Wilk test (p = 0.501) justifying the use of t-test.
https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_Fig2_HTML.jpg
Figure 2

Design of the experiment. Aggregation of untreated sample (without adding the flavonoid, AUC 0) and the sample of flavonoid (AUC) are measured. If the difference of the aggregations is greater than 5% the measurement of additional two citrated bloods is performed. Otherwise, double concentration of flavonoid is taken and the first step is repeated. If the flavonoid in the analysed concentration shows statistically lower aggregation compared to the untreated sample (t-test) the analysed concentration is equal to minimal antiaggregatory concentration (MINaAC). If not analysis is performed from the beginning with double the concentration of flavonoid. This presumes that the analyzed concentration is not the first analysed (n > 1), else, the analysis is performed from beginning using the half of the concentration of flavonoid. Example of prunetin is given. Aggregation of analysed concentration of prunetin: 3.8 μM is not greater than aggregation of the untreated sample (58 U vs. 59 U). Thus additional measurement with double concentration (7.6 μM) of prunetin is performed. As the difference of aggregation is greater than 5% (ΔAUC = 17%) measurements on two additional citrated blood samples were performed. The concentration obtained is statistically different compared to the untreated sample (p = 0.033) thus minimal antiaggregatory concentration of prunetin is equal 7.6 μM. Note that red and blue lines in charts indicate two parallel measurements of the same sample. If the deviation between these two measurements is greater than 10%, quality control flag appears and measurements should be repeated.

Results and Discussion

All analyzed flavonoids exhibited antiaggregatory activity with MINaAC ranging from 119 nM to 122 μM.

Pinocembrine-7-methylether has lower MINaAC than pinocembrin, thus methylated derivates of flavanons have greater antiaggregatory effect. Most potent flavanones are p-O-methylated derivates at B-ring (Table 1).

Monohydroxylated flavones are most potent if substituted at the position 6 of the A-ring (6-hydroxyflavone, Table 2). However, most naturally occurring flavonoids are hydroxylated at position 7 (7-hydroxyflavone), thus having lower antiaggregatory effect. Increase in number of hydroxyl groups does not influence antiaggregatory effect (flavone, chrysin, apigenin). Methylation increases antiaggregatory effect, the same as it does in case of flavones (tectochrysin > chrysin). If the flavone has more than four substituents the activity decreases, even if methylated (diosmetin, luteolin, tangeretin).

Generally hydoxylated flavanons have greater antiaggregatory effect than flavones (pinocembrin > chrysin), opposite to methylated derivates (hesperetin > diosmetin, isosakuranetin > acacetin, pinocembrin-7-methylether = tectochrysin).

Comparing monohydroxylated flavanonols to monohydroxylated flavones antiaggregatory effect is higher (3,6-dihydroxyflavone > 6-hydroxyflavone, 3,7-dihydroxyflavone > 7-hydroxyflavone). As it is the case with flavones, increase in number of substituents (four and more) decreases, while methylation increases antiaggregatory effect (syringetin > rhamnetin > quercetin, Table 3).

Isoflavonoids are less potent antiaggregatory agents, but the same as for flavonoids applies: increase in hydroxylation decreases while methylation increases antiaggregatory effect (Table 4). This is probably due to greater volume and higher lipophilicity of the methyl radical (V = 37.15, π = -0.09) compared to hydroxyl group (V = 11.79, π = -0.74). Higher lipophilicity can lead to significant interactions with the platelet's membrane by increasing rigidity. The membrane is stabilized and the appearance of the receptors - integrins e.g. GPIIa/IIIb at the platelet surface is limited [1921].

Epicatechin, present in wine, was the only catechin analyzed (Table 5). It has greater antiaggregatory effect compared to flavone and flavanonol parallels, namely luteolin and quercetin.

Based on these observations, structure activity relationship between flavonoids (Figure 1) and antiaggregatory activity reveals that:
  • double bond at the position C2-C3 increases activity for hydroxylated derivates, but decreases activity for methylated derivates at the ring A and B,

  • hydroxyl group at the position C3 increases antiaggregatory activity,

  • transfer of B ring from C2 to C3 decreases activity (isoflavonoids),

  • absence of carbonyl group at the position C4 increases activity,

  • most potent flavonoids are substituted at the position C6 of the ring A,

  • O-methylation of the rings A and B increases activity,

  • if the rings A and B have 4 and more radicals activity decreases.

The results of antiaggregatory effect of flavonoids were compared to clopidogrel which acts as antagonist of ADP and serves as positive control in the experiment (Table 5). Although results for clopidogrel are comparable to results of the most potent flavonoids 3,6-dihydroxyflavone and syringetin, this should be interpreted with caution. Clopidogrel is a pro-drug whose metabolic activation to some extent can occur in vitro as main enzyme responsible for activation CYP2C19 is present in different tissues including the blood [22].

Dell'Agli et al. reported that inhibitory effect on platelet aggregation (induced by thrombin) of 10 μM concentration of individual compound followed the order: luteolin, quercetin and apigenin, the last being inactive [9]. In our study MINaAC followed the other arrangement: apigenin (3.815 μM), luteolin (7.629 μM), quercetin (15.259 μM), using ADP to induce aggregation.

Comparing the sets of flavonoids analyzed in our research to the work of Navarro-Nuñez et al. where antigreggatory effect was expressed as percentage of inhibition of SQ 29548 binding to thromboxane A2 (TxA2) receptor, apigenin was the most potent antagonist of aggregation [23]. Thus, it achieves antiaggregatory effect both through antagonism of thromboxane A2 receptors as well as ADP receptors. However, genistein was next potent antagonist of TxA2 receptors, contrary to our research where isoflavonoids showed lower antagonism to ADP receptors compared to other classes of flavonoids. Hesperetin has MINaAC of 1.907 μM, ten to thirty times lower than reported by Jin et al., as expected due to usage of strong agonists of aggregation (collagen, arachidonic acid) [17].

The daily consumption of flavonoids is reported to be m = 23 mg per day [24]. If we take into account that absorption of flavonoid aglycone is f = 24% (as reported for quercetin [25]) of the consumed dose it would mean that concentration which can be achieved with normal diet is:
https://static-content.springer.com/image/art%3A10.1186%2F1475-2891-10-73/MediaObjects/12937_2011_Article_404_Equa_HTML.gif

where M represents average molar mass of flavonoid being 300 g/mol and V total blood volume of 5 L.

The most potent flavonoids cause minimal antiaggregatory effect in even lower concentrations: 3,6-dihyroxyflavone, syringetin (MINaAC = 0.119 μM), 6-hyroxyflavone, pinocembrin-7-methylether, tectochrysin, rhamnetin and isosakuranetin (MINaAC = 0.954 μM). These levels of flavonoids in serum have been experimentally confirmed for the most commonly consumed flavonoids: hesperetin and naringenin from orange juice, and epi/catechins from coco and green tea - ranging from 0.01 to 1.1 μM for individual flavonoid [2629]. This is contrary to findings of Janssen et al. that flavonoids are active in concentrations that can not be achieved in vivo [13].

Conclusions

This work provides insight in the antiaggregatory activity of a relatively large set of flavonoid aglycons measured by standardized impendance aggregometry in whole blood against ADP as an inductor. SAR of flavonoids shows that increase in the number of hydroxyl groups at the rings A and B, decreases activity. On the other hand, if O-methyl groups are introduced activity increases. This indicates that the size/volume and lipophilicity of the radical is important factor, which should be confirmed in further QSAR prediction studies.

The results obtained suggest that even a daily consumption of flavonoids can effect aggregation of platelets. As flavonoids are ubiquitous substances in plants, this work can serve as source of information for further assessment of food influence on antiaggregation/anticoagulation treatment.

Declarations

Acknowledgements

This work was supported by the Ministry of Science, Education and Sports of the Republic of Croatia (project No. 006-0061117-1237 - MMŠ).

Authors’ Affiliations

(1)
Faculty of Pharmacy and Biochemistry, Department of Medicinal Chemistry, University of Zagreb
(2)
Department of Clinical Laboratory Diagnostics
(3)
Croatian Institute of Transfusion Medicine, Department of Platelet and Leukocyte Immunology
(4)
Agency for Medicinal Products and Medical Devices of Croatia

References

  1. Sweetman S: Martindale: The Complete Drug Reference. 2011, London: Pharmaceutical PressGoogle Scholar
  2. de Lange DW, Verhoef S, Gorter G, Kraaijenhagen RJ, van de Wiel A, Akkerman JW: Polyphenolic grape extract inhibits platelet activation through PECAM-1: an explanation for the French paradox. Alcohol Clin Exp Res. 2007, 31: 1308-1314. 10.1111/j.1530-0277.2007.00439.x.View ArticlePubMedGoogle Scholar
  3. Leifert WR, Abeywardena MY: Cardioprotective actions of grape polyphenols. Nutr Res. 2008, 28: 729-737. 10.1016/j.nutres.2008.08.007.View ArticlePubMedGoogle Scholar
  4. Sumpio BE, Cordova AC, Berke-Schlessel DW, Qin F, Chen QH: Green tea, the "Asian paradox," and cardiovascular disease. J Am Coll Surg. 2006, 202: 813-825. 10.1016/j.jamcollsurg.2006.01.018.View ArticlePubMedGoogle Scholar
  5. Medić-Šarić M, Rastija V, Bojić M, Maleš Ž: From functional food to medicinal product: systematic approach in analysis of polyphenolics from propolis and wine. Nutr J. 2009, 8: 33-10.1186/1475-2891-8-33.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Akhlaghi M, Bandy B: Mechanisms of flavonoid protection against myocardial ischemia-reperfusion injury. J Mol Cell Cardiol. 2009, 46: 309-317. 10.1016/j.yjmcc.2008.12.003.View ArticlePubMedGoogle Scholar
  7. Lill G, Voit S, Schrör K, Weber AA: Complex effects of different green tea catechins on human platelets. FEBS Lett. 2003, 546: 265-270. 10.1016/S0014-5793(03)00599-4.View ArticlePubMedGoogle Scholar
  8. Pignatelli P, Di Santo S, Buchetti B, Sanguigni V, Brunelli A, Violi F: Polyphenols enhance platelet nitric oxide by inhibiting protein kinase C-dependent NADPH oxidase activation: effect on platelet recruitment. FASEB J. 2006, 20: 1082-1089. 10.1096/fj.05-5269com.View ArticlePubMedGoogle Scholar
  9. Dell'Agli M, Maschi O, Galli GV, Fagnani R, Dal Cero E, Caruso D, Bosisio E: Inhibition of platelet aggregation by olive oil phenols via cAMP-phosphodiesterase. Br J Nutr. 2008, 99: 945-951.View ArticlePubMedGoogle Scholar
  10. Freedman JE, Parker C, Li L, Perlman JA, Frei B, Ivanov V, Deak LR, Iafrati MD, Folts JD: Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Circulation. 2001, 103: 2792-2798.View ArticlePubMedGoogle Scholar
  11. Guerrero JA, Lozano ML, Castillo J, Benavente-García O, Vicente V, Rivera J: Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor. J Thromb Haemost. 2005, 3: 369-376. 10.1111/j.1538-7836.2004.01099.x.View ArticlePubMedGoogle Scholar
  12. Nakahata N: Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther. 2008, 118: 18-35. 10.1016/j.pharmthera.2008.01.001.View ArticlePubMedGoogle Scholar
  13. Janssen K, Mensink RP, Cox FJ, Harryvan JL, Hovenier R, Hollman PC, Katan MB: Effects of the flavonoids quercetin and apigenin on hemostasis in healthy volunteers: results from an in vitro and a dietary supplement study. Am J Clin Nutr. 1998, 67: 255-262.PubMedGoogle Scholar
  14. Weng JR, Chan SC, Lu YH, Lin HC, Ko HH, Lin CN: Antiplatelet prenylflavonoids from Artocarpus communis. Phytochemistry. 2006, 67: 824-829. 10.1016/j.phytochem.2006.01.030.View ArticlePubMedGoogle Scholar
  15. Heptinstall S, May J, Fox S, Kwik-Uribe C, Zhao L: Cocoa flavanols and platelet and leukocyte function: recent in vitro and ex vivo studies in healthy adults. J Cardiovasc Pharmacol. 2006, 47 (Suppl 2): S197-205.View ArticlePubMedGoogle Scholar
  16. Hubbard GP, Wolffram S, Lovegrove JA, Gibbins JM: Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. J Thromb Haemost. 2004, 2: 2138-2145. 10.1111/j.1538-7836.2004.01067.x.View ArticlePubMedGoogle Scholar
  17. Jin YR, Han XH, Zhang YH, Lee JJ, Lim Y, Chung JH, Yun YP: Antiplatelet activity of hesperetin, a bioflavonoid, is mainly mediated by inhibition of PLC-gamma2 phosphorylation and cyclooxygenase-1 activity. Atherosclerosis. 2007, 194: 144-152. 10.1016/j.atherosclerosis.2006.10.011.View ArticlePubMedGoogle Scholar
  18. Pignatelli P, Pulcinelli FM, Celestini A, Lenti L, Ghiselli A, Gazzaniga PP, Violi F: The flavonoids quercetin and catechin synergistically inhibit platelet function by antagonizing the intracellular production of hydrogen peroxide. Am J Clin Nutr. 2000, 72: 1150-1155.PubMedGoogle Scholar
  19. Furusawa M, Tsuchiya H, Nagayama M, Tanaka T, Nakaya K, Iinuma M: Anti-platelet and membrane-rigidifying flavonoids in brownish scale of onion. J Health Sci. 2003, 49: 475-480. 10.1248/jhs.49.475.View ArticleGoogle Scholar
  20. Hendrich AB: Flavonoid-membrane interactions: possible consequences for biological effects of some polyphenolic compounds. Acta Pharmacol Sin. 2006, 27: 27-40. 10.1111/j.1745-7254.2006.00238.x.View ArticlePubMedGoogle Scholar
  21. O'Malley BA: Primary Hemostasis. Clinical Laboratory Hematology. Edited by: McKenzie SB, Williams JL. 2010, New York: Pearson, 612-638. 2Google Scholar
  22. Božina N, Bradamante V, Lovrić M: Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol. 2009, 60: 217-242.PubMedGoogle Scholar
  23. Navarro-Núñez L, Castillo J, Lozano ML, Martínez C, Benavente-García O, Vicente V, Rivera J: Thromboxane A2 receptor antagonism by flavonoids: structure-activity relationships. J Agric Food Chem. 2009, 57: 1589-1594. 10.1021/jf803041k.View ArticlePubMedGoogle Scholar
  24. Hertog MG, Hollman PC, Katan MB, Kromhout D: Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr Cancer. 1993, 20: 21-29. 10.1080/01635589309514267.View ArticlePubMedGoogle Scholar
  25. Hollman PC, de Vries JH, van Leeuwen SD, Mengelers MJ, Katan MB: Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr. 1995, 62: 1276-1282.PubMedGoogle Scholar
  26. Stalmach A, Mullen W, Steiling H, Williamson G, Lean ME, Crozier A: Absorption, metabolism, and excretion of green tea flavan-3-ols in humans with an ileostomy. Mol Nutr Food Res. 2010, 54: 323-334. 10.1002/mnfr.200900194.View ArticlePubMedGoogle Scholar
  27. Gardana C, Guarnieri S, Riso P, Simonetti P, Porrini M: Flavanone plasma pharmacokinetics from blood orange juice in human subjects. Br J Nutr. 2007, 98: 165-172. 10.1017/S0007114507699358.View ArticlePubMedGoogle Scholar
  28. Bredsdorff L, Nielsen IL, Rasmussen SE, Cornett C, Barron D, Bouisset F, Offord E, Williamson G: Absorption, conjugation and excretion of the flavanones, naringenin and hesperetin from alpha-rhamnosidase-treated orange juice in human subjects. Br J Nutr. 2010, 103: 1602-1609. 10.1017/S0007114509993679.View ArticlePubMedGoogle Scholar
  29. Mullen W, Archeveque MA, Edwards CA, Matsumoto H, Crozier A: Bioavailability and metabolism of orange juice flavanones in humans: impact of a full-fat yogurt. J Agric Food Chem. 2008, 56: 11157-11164. 10.1021/jf801974v.View ArticlePubMedGoogle Scholar

Copyright

© Bojićć et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement